Ruibosi
Latest round
- Series C
Last raised
- Dec 2025
Total raised
- $42M
Investors
- 8
About Ruibosi
, trading as Ruibosi, operates as a biotechnology company that focuses on cellular technology and product development. Lin Chen, CTO of the company, graduated from Tsinghua University and serves as the Secretary General of the International Society for Neuroprosthetics. The company has 6 intellectual property patents. In 2022, it was recognized as the National High-tech Enterprise. The company's business can be divided into two categories, which are biotechnology technology and biopharmaceutical research and development. It has stem cells, ECIWEP targeted protein extraction process, and other cellular biotechnology. The biological drugs include nerve repair, cartilage repair skin hair follicle repair, and other drug research and development. The company's revenue is primarily generated from the development and commercialization of biopharmaceuticals and biomedical consumables, particularly in neurological disease treatment, stem cell therapy, and protein polymer-based drug products.
Who invested in Ruibosi
8 investors across 5 rounds
See all investors in Ruibosi
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ruibosi
Who invested in Ruibosi?
Ruibosi has 8 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ruibosi raised?
Ruibosi has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Ruibosi last raise money?
Ruibosi's most recent round on record is a Series C, in Dec 2025.
What does Ruibosi do?
, trading as Ruibosi, operates as a biotechnology company that focuses on cellular technology and product development.
Where is Ruibosi headquartered?
Ruibosi is headquartered in Beijing, China.
Which VCs invest in companies like Ruibosi?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Ruibosi's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Ruibosi? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.